The prognostic value of MRD in CLL

(1:19)

Evaluating the prognostic value of time to metastasis in metachronous mHSPC

(5:54)

The prognostic value of MRD negativity

(3:14)

Prognostic Value of Post-PCI Angio-IMR in NSTEMI Patients | JACC: CV Interventions

(5:45)

The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma

(4:26)

Prognostic value of cytogenic findings in RCC

(55)

Prognostic value of the updated ICC and WHO classifications for MDS

(5:14)

Jerome Galon on the Prognostic Value of Immunoscore

(1:33)

📢 What is a Market Value Adjustment (MVA) and How Does It Work? 🚀

(4:33)

The prognostic value of structural heterogeneity of chromosome 1q in multiple myeloma

(1:53)

What is the prognostic value of STE?

(2:9)

Assessing the prognostic value of NGS-based MRD in adults with ALL undergoing SCT

(2:41)

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast Cancer

(49)

The prognostic value of self-reported fatigue on overall survival in patients with MDS

(1:6)

The Prognostic Value of Molecular Testing

(2:53)

Prognostic value of evaluating MRD dynamics in multiple myeloma maintenance

(18:24)

The prognostic value of PRLs in MS progression

(4:40)

The prognostic value of patient-reported outcomes in MDS

(1:30)

Evaluating the prognostic value of PSMA PET/CT in mCRPC

(10:1econd)

Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia

(1:34)